Richard Kim, MD: Using Durvalumab + Gemcitabine-Cisplatin in Clinical Practice
Dr. Kim explains his decision-making process when selecting a treatment for patients with advanced or metastatic biliary tract cancer (BTC), highlighting the importance of thinking beyond simply choosing a chemotherapy regimen. He highlights key outcomes from the TOPAZ-1 trial, which showed that adding durvalumab to gemcitabine-cisplatin improved overall survival in patients with advanced or metastatic BTC.
Topics covered:
- Making the right treatment decision for patients with advanced or metastatic BTC
- Overall survival data from the TOPAZ-1 clinical trial
- Achieving more durable disease control and long-term survival with durvalumab plus gemcitabine-cisplatin
